CBD demonstrates strong anti-inflammatory properties when applied topically, targeting inflamed skin tissues by suppressing mediators and supporting barrier function, making it suitable for acne, psoriasis, and dermatitis. Human trials provide growing support for these effects.
Clinical studies have shown topical CBD reduces gingival inflammation and bleeding in periodontitis patients (Jirasek et al., 2024). Similarly, CBD-enriched ointments improved skin parameters and symptom scores in inflammatory conditions like psoriasis and atopic dermatitis (Palmieri et al., 2019; Burczyk et al., 2025).
Additional trials confirm topical CBD mitigates UV-induced erythema and related inflammatory damage, highlighting its antioxidant and anti-inflammatory actions in human skin (McCormick et al., 2024). Overall, these findings support topical CBD as a well-tolerated natural option for skin inflammation.
References
-
Jirasek, P., et al. (2024). Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo-controlled double-blind randomized clinical trial with cannabidiol. Journal of Periodontal Research, 59(3), 468–479. https://doi.org/10.1111/jre.13234
-
Palmieri, B., Vadala, M., & Romano, B. (2019). A therapeutic effect of CBD-enriched ointment in inflammatory skin diseases and cutaneous scars. La Clinica Terapeutica, 170(2), e93–e99. https://doi.org/10.7417/CT.2019.2116
-
Burczyk, D. D., et al. (2025). Evaluation of biophysical parameters of the skin of patients with atopic dermatitis after application of an ointment containing 30% cannabidiol and 5% cannabigerol. Clinical, Cosmetic and Investigational Dermatology, 18, 649–662. https://doi.org/10.2147/CCID.S472746
-
McCormick, E., et al. (2024). Topical nanoencapsulated cannabidiol cream as an innovative strategy combating UV-A-induced nuclear and mitochondrial DNA injury: A pilot randomized clinical study. Journal of the American Academy of Dermatology, 91(5), 855–862. https://doi.org/10.1016/j.jaad.2024.06.088
